🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy.

PMID: 41611241 · DOI: 10.1136/jitc-2025-013381 · Journal for immunotherapy of cancer, 2026 · Caifeng Gong, Shuhui You, Qi Zhang, Zhenrong Yang, Xinyu Bi, Hong Zhao, Yongkun Sun, Jianguo Zhou, Weiqi Rong, Jianjun Z
📄 Abstract

This study was conducted to assess the clinical significance of programmed cell death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) as predictive biomarkers for the efficacy of PD-(L)1 inhibitor-based treatment in advanced hepatocellular carcinoma (HCC). We enrolled 59 patients with unresectable HCC who received immunotherapy-based treatment and analyzed CTCs, PD-L1 CTCs were detected in 86.4% (51/59) of patients, with a PD-L1-positive rate of 83.7% (41/49). Compared with the "PD-L1 PD-L1

Confidence: 0.12 · 6 полей извлечено
Идентификация (6 полей)
Target
PD-L1
0.95
Alt. target
programmed cell death-ligand 1
0.95
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
PD-L1 expression on circulating tumor cells in hepatocellular carcinoma patients
0.90
In vitro
0.00
In vivo
0.00
In silico
0.00
Genetic association
0.00
Ex vivo
Analysis of circulating tumor cells from patients with hepatocellular carcinoma
0.90
Animal model
0.00
Diet/model
0.00
Клиника (11 полей)
Drug
0.00
Indication
hepatocellular carcinoma
0.90
Patient subgroups
patients with PD-L1-positive circulating tumor cells
0.80
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
0.00